We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fluorescent Markers Illuminate Cancer Intraoperatively

By HospiMedica International staff writers
Posted on 19 Feb 2020
A new study shows that intraoperative fluorescent markers can be used to illuminate and target non-small-cell lung cancer (NSCLC), improving patient outcomes. More...


Under development at On Target Laboratories ((Lafayette, IN, USA), based on technology developed by Purdue University (Lafayette, IN, USA), OTL38 is an analog of folate (vitamin B9) conjugated to a near-infrared (NIR) fluorescent dye. A small single dose of the compound is administered via intravenous (IV) infusion prior surgery. A dedicated near-infrared (NIR) imaging system is then used to identify the fluorescent signal generated after the agent binds to folate receptor-alpha (FRα). Since NIR light at 796 nm penetrates several centimeters into tissue, OTL38 can visualize tumors under the surface.

In a multi-institutional Phase 2 clinical trial involving 92 patients with NSCLC conducted over 18 months, OTL38 improved outcomes for 26% of patients undergoing pulmonary resection for NSCLC, and helped uncover otherwise unlocalizable lesions in 11 patients (12%). In addition, 10 supplementary cancers were found in seven patients, (8%), and inadequate surgical margins were identified in eight patients (9%). The study was presented at the 56th annual meeting of the Society of Thoracic Surgeons (STS), held during January 2020 in New Orleans (LA, USA).

“OTL38 is the first technique that is specific to imaging adenocarcinomas of the lung, which is one of the most common types of invasive lung cancer,” said cardiothoracic surgeon Inderpal Sarkaria, MD, of the University of Pittsburgh Medical Center (PA, USA). “NIR imaging with OTL38 may be a powerful tool to help surgeons significantly improve the quality of lung cancer surgery by more clearly identifying tumors and allowing the surgeon to better see and completely remove them, one of the most vital components in the overall care of patients with this disease.”

Folate can be used like a Trojan horse to sneak an imaging agent or drug into a cancer cell. About 80% of endometrial, lung, kidney, and ovarian cancer exhibit high rates of FR-α receptor expression, and 50% of breast and colon cancers also express the receptor.

Related Links:
On Target Laboratories
Purdue University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.